A detailed history of Regions Financial Corp transactions in United Therapeutics Corp stock. As of the latest transaction made, Regions Financial Corp holds 561 shares of UTHR stock, worth $211,497. This represents 0.0% of its overall portfolio holdings.

Number of Shares
561
Holding current value
$211,497
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$311.04 - $363.55 $174,493 - $203,951
561 New
561 $201,000
Q1 2023

May 12, 2023

SELL
$212.99 - $276.17 $1,064 - $1,380
-5 Reduced 0.52%
950 $213,000
Q4 2022

Feb 03, 2023

SELL
$205.95 - $280.43 $24,508 - $33,371
-119 Reduced 11.08%
955 $266,000
Q3 2022

Nov 03, 2022

SELL
$203.3 - $244.17 $8,132 - $9,766
-40 Reduced 3.59%
1,074 $225,000
Q2 2022

Jul 25, 2022

SELL
$174.81 - $241.14 $33,913 - $46,781
-194 Reduced 14.83%
1,114 $263,000
Q1 2022

Apr 25, 2022

SELL
$166.16 - $213.96 $3,655 - $4,707
-22 Reduced 1.65%
1,308 $235,000
Q4 2021

Jan 31, 2022

SELL
$184.32 - $216.08 $4,055 - $4,753
-22 Reduced 1.63%
1,330 $287,000
Q3 2021

Nov 04, 2021

SELL
$179.86 - $214.88 $13,849 - $16,545
-77 Reduced 5.39%
1,352 $250,000
Q2 2021

Jul 27, 2021

SELL
$170.47 - $211.93 $16,535 - $20,557
-97 Reduced 6.36%
1,429 $256,000
Q1 2021

Jun 02, 2021

SELL
$153.94 - $174.85 $30,018 - $34,095
-195 Reduced 11.33%
1,526 $255,000
Q4 2020

Feb 05, 2021

BUY
$101.87 - $151.79 $175,318 - $261,230
1,721 New
1,721 $261,000
Q3 2020

Oct 15, 2020

SELL
$99.9 - $121.13 $221,778 - $268,908
-2,220 Closed
0 $0
Q2 2020

Jul 27, 2020

BUY
$92.74 - $125.82 $205,882 - $279,320
2,220 New
2,220 $268,000
Q2 2019

Jul 19, 2019

SELL
$76.06 - $120.81 $13,690 - $21,745
-180 Closed
0 $0
Q4 2017

Jan 18, 2018

BUY
$118.58 - $151.28 $21,344 - $27,230
180
180 $27,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17.2B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Regions Financial Corp Portfolio

Follow Regions Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Regions Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Regions Financial Corp with notifications on news.